Mikart

As the pharmaceutical industry evolves, the exploration of alternative and plant-derived therapies has moved from the fringe to the forefront of innovation. Cannabinoids and psilocybin—once primarily associated with natural wellness communities—are now the focus of serious research and emerging regulatory pathways aimed at treating a wide range of conditions, including chronic pain, epilepsy, anxiety, depression, and PTSD. At Mikart, we recognize the potential of these therapies and are well-positioned to support companies seeking to bring them to market....

Navigating Emerging Therapeutics: How Mikart Supports Cannabinoid and Psilocybin Drug Development – Mikart As the pharmaceutical industry evolves, the exploration of alternative and plant-derived therapies has moved from the fringe to the forefront...

In recent years, the pharmaceutical industry has witnessed a significant shift towards liquid suspension formulations, particularly within the Contract Development and Manufacturing Organization (CDMO) sector. Various factors, including the need for patient-centric drug delivery systems, technological advancements, and evolving market demands, drive this trend. 1. Introduction to Liquid Suspensions in the CDMO Industry Liquid suspensions are heterogeneous mixtures in which fine solid particles are dispersed within a liquid medium....

Liquid Suspension Trends in the CDMO Space – Mikart In recent years, the pharmaceutical industry has witnessed a significant shift towards liquid suspension formulations, particularly within the Contract Development...

In the highly competitive pharmaceutical industry, speed is everything. The faster a product can move from concept to clinical trials, the better the chances of meeting market demands and staying ahead of competitors. At Mikart, we understand the importance of accelerating the development process, and that’s why we offer a non-GMP small-scale laboratory dedicated to early-stage product development. Key Advantages of Using Our Non-GMP Laboratory…...

Accelerating Product Development with Mikart’s Non-GMP Small-Scale Laboratory – Mikart Discover how Mikart's non-GMP small-scale laboratory accelerates product development with rapid prototyping, cost efficiency and support

Liquid-oral formulations, from solutions to syrups, come with their fair share of complexities. Think solubility woes, stability concerns, and taste challenges. But fear not, for where there's a will, there's a way, especially when you've got Mikart, a dynamic Contract Development and Manufacturing Organization (CDMO) in your corner. Why partner up? For starters, Mikart brings a boatload of expertise to the table....

Sailing Smoothly: Partnering with a CDMO for Liquid-Oral Formulation Development – Mikart Liquid-oral formulations, from solutions to syrups, come with their fair share of complexities. Think solubility woes, stability concerns, and taste...

In the fast-paced and highly competitive landscape of pharmaceutical development and manufacturing, the role of project managers cannot be overstated. From navigating complex timelines to ensuring seamless communication between stakeholders, project managers serve as the linchpin in successful project ex*****on. One critical aspect of their responsibilities is selecting the right Contract Development and Manufacturing Organization (CDMO) partner—a decision that can profoundly impact project outcomes and overall success....

The Crucial Role of Project Managers in Selecting a CDMO Partner – Mikart In the fast-paced and highly competitive landscape of pharmaceutical development and manufacturing, the role of project managers cannot be overstated....

age forms that emphasize patient convenience and meeting the specific needs of pediatric and geriatric populations are creating more demand for coating solutions. The ability of specially designed coatings to provide both taste-masking and controlled-release functionalities is driving interest in their use for reformulation of oral solid dosage products that are losing patent protection. In particular, as more products leverage ODT, multiparticulate, sprinkle, and other formats that enable differentiation but require prevention of exposure of the API in the mouth, film coatings are becoming more widely used....

Addressing Swallowing and Palatability Issues with Patient-Friendly Dosage Forms – Mikart age forms that emphasize patient convenience and meeting the specific needs of pediatric and geriatric populations are creating more demand...

Mikart, an oral dosage focused contract development and manufacturing organization (CDMO), is moving beyond generic manufacturing to support customers from non-GMP preclinical work to full-scale GMP commercial volumes with a recently expanded range of capabilities, including formulation development, manufacturing, and serialized packaging. Michelle Hall, Vice President of Marketing at Mikart, shares how customers benefit from its end-to-end service offering. Mikart emphasizes value-added services and transparent, flexible business terms as the key to supporting its customers that rely on outsourcing to bring their candidates to the clinic and the market, with…...

On the Journey to Support Drug Developers With End-to-End Outsourcing – Mikart Mikart, an oral dosage focused contract development and manufacturing organization (CDMO), is moving beyond generic manufacturing to support customers from...

Happy Independence Day!
As we celebrate this Independence Day, remember those who have sacrificed and continue to sacrifice for our freedom. We express our deepest gratitude to the brave men and women in uniform who protect our liberties and ensure our safety.

Mikart commemorates Juneteenth, a celebration of freedom and equality! Today let's reflect, learn, and strive for a future where all embrace equality, justice, and freedom.

The Unapproved Drugs Initiative (UDI) is a program launched by the Food and Drug Administration (FDA) in 2006 to remove unapproved drugs from the market and ensure that all drugs meet modern standards of safety, effectiveness, quality, and labeling. Unapproved drugs are those that have not been evaluated by the FDA for safety and effectiveness, but are still marketed and sold in the United States....

Unapproved Drugs Initiative – Mikart The Unapproved Drugs Initiative (UDI) is a program launched by the Food and Drug Administration (FDA) in 2006 to remove...

Happy St. Patrick's Day from the team at Mikart! May your day be touched with some Irish luck. 🌈 🍀

Join us in celebrating International Women’s Day!
At Mikart, we value women. More than 58% of our employees are women and 52% are in leadership roles!

Happy Women’s Day to all the Incredible Women out there!